Use LEFT and RIGHT arrow keys to navigate between flashcards;
Use UP and DOWN arrow keys to flip the card;
H to show hint;
A reads text to speech;
60 Cards in this Set
- Front
- Back
Goals of antimicrobial therapy
|
Resolution of infection, avoidance of resistance
|
|
Evidence of resolution of infection
|
Resolution of clinical signs
|
|
This use of drugs in food animals has contributed to resistant microbes in foods
|
Antimicrobials as growth promotants
|
|
Example organisms for which resistance has developed in food animals
|
Campylobacter, Salmonella
|
|
True or False: Bacteria move FROM humans TO animals
|
TRUE
|
|
The term used to refer to transfer of microorganisms from animals to humans and from humans to animals, respectively
|
Zoonoses, reverse zoonoses
|
|
The AVMA has directed specialty groups to generate these guidelines
|
Judicous Antimicrobial Use Guidelines
|
|
Define "antimicrobial"
|
An agent intended to harm or suppress a microbe
|
|
Define "Antibiotic"
|
An antimicrobial of natural origin
|
|
Examples of natural antibiotics
|
Pencillin, gentamicin, vancomycin, others
|
|
The term that refers to a natural antibiotic that has been modified
|
Semi-synthetic antimicrobial
|
|
An example of a semi-synthetic antimicrobial
|
Amoxicillin, ampicillin, ticarcillin
|
|
An example of a synthetic antimicrobial
|
Any fluorinated quinolone
|
|
An example of a Gram positive organism generally characterized by low MIC
|
Streptococcus toward for example, penicillns
|
|
An example of a Gram negative organism generally characterized by low MIC
|
Pasteurella toward many drugs
|
|
An example of a Gram positive organism often characterized by high MIC
|
Corynebacgterium, Staphylococcus
|
|
An example of a Gram negative organism generally characterized by high MIC
|
Pseduomonas, Enterobacter
|
|
An example of a gram negative organism that is inherently multidrug resistant
|
Pseudomonas aeruginosa
|
|
An example of a gram positive organism that is inhterently multidrug resistant
|
Enterococcus faecium
|
|
The term used to refer to organisms exquisitively sensitive to the effects of oxygen
|
Obligate anaerobes
|
|
A term used to refer to a resident population of microbes
|
Inoculum
|
|
The term used to refer to a representative isolate from an inoculum
|
A colony forming unit (CFU)
|
|
The term used to refer to a commensal which becomes a pathogen
|
An opportunist
|
|
The term used to refer to an organism capable of causing harm to the patient
|
Pathogen
|
|
Two factors that indicate that a cultured isolate is the infecting pathogen
|
Viability of growth, purity
|
|
A factor that indicates that a cultured isolate is a pathogen
|
Phagocytized organisms; selected molecular tests
|
|
In the urine, the number of CFU indicative of possible infection
|
10(3) to 10(5); 1,000 to 100,000
|
|
The term used to refer to normal flora that colonize the hose without causing harm
|
Commensals
|
|
Actions through which commensals may contribute to host health
|
Provide nutrients, control immune system, control populations of microbiota
|
|
These factors allow a microbe to cause harm
|
Virulence factors
|
|
The first step in judicious antimicrobial use
|
Assessing the need for teatment
|
|
The second step in judicous antimicrobial use
|
Identifying the infecting microbe/choose the drug
|
|
The third step in judicious antimicrobial use
|
Designing the dosing regimen
|
|
A method by which an infecting microbe can be identified based on historical data
|
Empirical selection
|
|
This method of identifying an infecting microbe is the most specific for the patient's infection
|
Culture and susceptibility testing
|
|
The most common organism causing urinary tract infection in dogs
|
Escherichia coli
|
|
The most common organism causing pyodrma in dogs
|
Staphylococcus pseudintermedius
|
|
A first tier drug effective for treatment first time urinary tract infection
|
amoxicillin/with or without clavulanic acid
|
|
An example of an infection that might respond better to local non-antimicrobial therapy
|
Feline Abscess, gutteral pouch disease in horses
|
|
Revealing this in the history of a patient causes an infection to become "complicated"
|
(Recent) previous antimicrobial therapy
|
|
This structure on gram negative organisms presents as a barrier to drug penetration
|
Lipopolysaccharide layer
|
|
These factors allow a microbe to cause harm to a patient
|
Virulence factors
|
|
Define a "wild type" organism
|
Retains original genome rather than genes for resistance
|
|
An indication from the patient of "how much of an antimicrobial is needed" to target an infecting pathogen
|
Minimum inhibitory concentration
|
|
A population surrogate from indicators of "how much of an antimicrobial is needed" to target an infecting isolate
|
90th percentile of a population of MIC (MIC 90)
|
|
The "pharmacodynamic" indicator for microbials
|
Minimum inhibitory concentration
|
|
A "pharmacokinetic" parameter that indicates "how much drug is achieved" in the patient
|
Peak plasma drug concentration (Cmax)
|
|
The non-regulatory agency that sets standards for diagnostic- inlcuding Culture and Susceptibility - testing
|
Clinical Laboratory Standards Institute (CLSI)
|
|
This system allows simultaneous testing of multiple (eg, 8) drugs towards a microbe on a single plate
|
Agar gel diffusion
|
|
This system of susceptibility testing provides a concentration that is anticipated to be effective
|
Tube dilution procedures
|
|
The MIC of an isolate for amikacin is 16 mcg/ml and for enrofloxacin, 0.5 mcg/ml. As such, the isolate is more susceptible to enrofloxacin. Select one: True, False or Insufficient Information (I)
|
I. You need to know Cmax. With Cmax provided, the statement would be true: comparing the Cmax to MIC, for enro at 4 mcg/ml (ratio = 8) the ratio is better compared to amikacin whose Cmax at the recommended dose is 64 mcg/ml (ratio = 4).
|
|
True or False: All susceptibility testing involves two fold serial dilutions (or increase) of the drug of interest
|
TRUE
|
|
True or False: All susceptibility testing is implemented at 0.25 to 8 mcg/ml
|
False: the range tested varies with the drug, reflecxting the Cmax achieved at the recommended dose
|
|
A basis for the ranges of concentrations tested on a susceptibility panel for each drug
|
The peak concentration of the drug achieved in the plasma at the recommended dose
|
|
An isolate is tested at concentrations that range from 0.125 to 2 mcg/ml. Growth occurs up to (that is, at 0.125, 0.25) but not including 0.5 mcg/ml. What is the MIC?
|
0.5 mcg/ml
|
|
An isolate is tested at concentrations that range from 4 to 64 mcg/ml. Growth occurs in all the wells, including that containing 64 mcg/ml. What is the MIC?
|
> 128 mcg/ml
|
|
An isolate has an MIC of 1 mcg/ml. The breakpoint is < 4 mcg/ml (susceptible) and >8 mcg/ml (resistant). What will CLSI indicate the isolate to be?
|
The isolate would be considered susceptible to the drug
|
|
True or False: An isolate designated as "susceptible" to a drug will have no resistance genes for that drug
|
False: The designation only refers to the susceptiblity test and whether or not the MIC is likely to be achieved in the patient at the recommended dose
|
|
True or False: The "S, I or R" designation indicates the likelihood that the MIC for an isolate can be achieved when the dose is administered as the recommended dose
|
TRUE
|
|
A class of drugs to which Enterococcus sp is ineffective
|
cephalosporins, aminoglycosides
|